A study characterizing the expression of CK5 in serous gynecological carcinomas of the ovaries, endometrium, fallopian tube, primary peritoneum, and cervix observed the highest level of CK5 expression in the cervical and ovarian serous carcinomas, with little to no reactivity in the endometrial, fallopian tube, or primary peritoneum serous carcinomas [24]. The gene discussed is KRT5; the disease is serous adenocarcinoma.